Abstract
All-trans retinoic acid (atRA) is the transcriptionally active product of vitamin A and induces gene expression via specific receptors at nM concentrations. Essential enzymes that regulate the local levels of atRA are the CYP26 members of the cytochrome P450 family, which catabolize atRA. Compounds that have been designed to inhibit these enzymes are known as Retinoic Acid Metabolic Blocking Agents (RAMBAs). Treatment with these compounds will raise endogenous atRA levels and may be therapeutic for the treatment of diseases that respond to high atRA concentrations, including several types of cancer as well as skin conditions such as psoriasis and acne. This review describes the mechanism of action of the RAMBAs and discusses the potential side effects of these compounds. atRA is highly teratogenic and the potential teratogenicity of the RAMBAs is described by comparison with the abnormalities resulting from null mutation of individual CYP26 genes. The possible effects of RAMBAs on the adult brain are also described that have the potential for harm but, in the right circumstances, may also be beneficial.
Keywords: Retinoic acid, CYP26, catabolism, caudal regression, limb defect, neurogenesis, hippocampus
Current Pharmaceutical Design
Title: Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Volume: 13 Issue: 29
Author(s): P. McCaffery and C. Simons
Affiliation:
Keywords: Retinoic acid, CYP26, catabolism, caudal regression, limb defect, neurogenesis, hippocampus
Abstract: All-trans retinoic acid (atRA) is the transcriptionally active product of vitamin A and induces gene expression via specific receptors at nM concentrations. Essential enzymes that regulate the local levels of atRA are the CYP26 members of the cytochrome P450 family, which catabolize atRA. Compounds that have been designed to inhibit these enzymes are known as Retinoic Acid Metabolic Blocking Agents (RAMBAs). Treatment with these compounds will raise endogenous atRA levels and may be therapeutic for the treatment of diseases that respond to high atRA concentrations, including several types of cancer as well as skin conditions such as psoriasis and acne. This review describes the mechanism of action of the RAMBAs and discusses the potential side effects of these compounds. atRA is highly teratogenic and the potential teratogenicity of the RAMBAs is described by comparison with the abnormalities resulting from null mutation of individual CYP26 genes. The possible effects of RAMBAs on the adult brain are also described that have the potential for harm but, in the right circumstances, may also be beneficial.
Export Options
About this article
Cite this article as:
McCaffery P. and Simons C., Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity, Current Pharmaceutical Design 2007; 13 (29) . https://dx.doi.org/10.2174/138161207782110534
DOI https://dx.doi.org/10.2174/138161207782110534 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Critical microRNAs in Lung Cancer: Recent Advances and Potential Applications
Anti-Cancer Agents in Medicinal Chemistry Natural Products Containing Olefinic Bond: Important Substrates for Semi-synthetic Modification Towards Value Addition
Current Organic Chemistry Monotherapy for the Treatment of Lymphedema in Children: A Review
Current Pediatric Reviews Hybrid Imaging in Evaluation of Abdominal Sarcoidosis
Current Medical Imaging H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma
Current Molecular Pharmacology Distinct Epigenetic Reprogramming, Mitochondrial Patterns, Cellular Morphology, and Cytotoxicity after Bee Venom Treatment
Recent Patents on Anti-Cancer Drug Discovery Sleep Disturbances in Lung Cancer Patients
Current Respiratory Medicine Reviews Carbon Nanoparticles in Mongolian Medicine Alleviate Acute Gastric Ulcer Induced by Ethanol by Regulating Fas/FasL Pathway
Current Drug Delivery Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry Structural and Mechanistic Bases of the Anticancer Activity of Natural Aporphinoid Alkaloids
Current Topics in Medicinal Chemistry Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Advances in Nano Drugs for Cancer Chemotherapy
Current Cancer Drug Targets Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Recent Developments in Particulate-Based Vaccines
Recent Patents on Drug Delivery & Formulation Recent Advances in the New Generation Taxane Anticancer Agents
Medicinal Chemistry An Update on Developments in Female Hormonal Contraception
Current Women`s Health Reviews Update On Emerging Antivirals For The Management Of Herpes Simplex Virus Infections: A Patenting Perspective
Recent Patents on Anti-Infective Drug Discovery Update on Evidence that Support a Role of Solar Ultraviolet-B Irradiance in Reducing Cancer Risk
Anti-Cancer Agents in Medicinal Chemistry Alterations in Homocysteine Metabolism Among Alcohol Dependent Patients - Clinical, Pathobiochemical and Genetic Aspects
Current Drug Abuse Reviews Aneuploidy-Inducing Mutations in Mitotic Checkpoint Protein hMad1-Carboxi Terminal Domain Analyzed by SAR and Computational Mutagenesis
Current Proteomics